-
The Medical Clinics of North America May 1984This article reviews, for the internist, recent advances in our understanding of the immunology and clinical characteristics of chronic lymphocytic leukemia (CLL). The... (Review)
Review
This article reviews, for the internist, recent advances in our understanding of the immunology and clinical characteristics of chronic lymphocytic leukemia (CLL). The method of treatment based on clinical staging of CLL and as practiced in the authors' clinic is detailed. It also provides an outline of possible investigation and therapy that may be expected in the coming years.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carmustine; Chromosomes, Human, 6-12 and X; Cyclophosphamide; Doxorubicin; Female; Humans; Leukemia, Lymphoid; Male; Melphalan; Middle Aged; Neoplasm Staging; Prednisone; T-Lymphocytes; Trisomy; Vincristine
PubMed: 6379339
DOI: 10.1016/s0025-7125(16)31123-3 -
CA: a Cancer Journal For Clinicians 1980At present, significant numbers of children with ALL enjoy prolonged survival without serious sequelae. All children should be given the benefit of treatment under the... (Review)
Review
At present, significant numbers of children with ALL enjoy prolonged survival without serious sequelae. All children should be given the benefit of treatment under the supervision of physicians experienced in childhood cancer. Risk factors should be properly assessed and children at high risk placed in innovative programs. Longterm follow-up of patients is essential to detect, as early as possible, potentially prohibitive toxicity.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Central Nervous System Diseases; Child; Humans; Leukemia, Lymphoid; Lymphocytes; Prognosis; Transplantation, Homologous
PubMed: 6769554
DOI: 10.3322/canjclin.30.3.158 -
Cancer Aug 1978Chronic lymphocytic leukemia (CLL) is the commonest type of leukemia seen in Western countries. It affects an older group of individuals than most other varieties of...
Chronic lymphocytic leukemia (CLL) is the commonest type of leukemia seen in Western countries. It affects an older group of individuals than most other varieties of leukemia, and men more often than women, in a ratio of 2:1. The incidence of CLL is significantly increased in some families. In most instances, CLL is due to the overgrowth or accumulation of immunoglobulin producing B lymphocytes. Hypogammaglobulinemia is a common feature, and anomalous immunoglobulin components occur in 3 to 5% of patients. The early symptoms and signs of CLL include fatigue, reduced exercise tolerance, enlarged lymph nodes, and splenomegaly. Fever, weight loss, and impairment of bone marrow function, with anemia, bleeding and susceptibility to infection are characteristic of severe or advanced disease. In the great majority of patients, the disease can be controlled for 6 to 10 or more years with simple regimens using chlorambucil or cyclophosphamide, often in combination with prednisone. Radiotherapy and splenectomy are useful in some instances. The terminal phase of the disease is characterized by exacerbation or increasing severity of the leukemia and the development of opportunistic infections associated with immunodeficiency.
Topics: Aged; Chlorambucil; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphoid; Male; Middle Aged; Neoplasm Staging; Prednisone
PubMed: 688176
DOI: 10.1002/1097-0142(197808)42:2+<941::aid-cncr2820420717>3.0.co;2-1 -
International Journal of Radiation... 1976
Topics: Chlorambucil; Drug Therapy, Combination; Humans; Leukemia, Lymphoid
PubMed: 972118
DOI: 10.1016/0360-3016(76)90029-8 -
Journal of the College of Physicians... Feb 2018Lymphoid (or lymphocytic/lymphoblastic) leukemia, one of two major types of leukemias (lymphoid and myeloid), is divided into two subtypes, acute lymphoid leukemia (ALL)... (Review)
Review
Lymphoid (or lymphocytic/lymphoblastic) leukemia, one of two major types of leukemias (lymphoid and myeloid), is divided into two subtypes, acute lymphoid leukemia (ALL) and chronic lymphocytic leukemia (CLL), depending on the maturation stage and speed of multiplication of the bone marrow lymphocytes. Early diagnosis and treatment can make the difference between life and death. Advancements in the field of proteomics may allow the development of early biomarkers and more effective agents to combat both these types of cancer, and to better understand the underlying mechanisms of the disease. The aim of this review was to elucidate the pathophysiology of lymphocytic leukemia using cancer proteomics techniques from 2007 until 2017. Only relevant original research articles archived in the Science Direct, PubMed and/or the Google Scholar databases within this period were included, which were a total of 30 studies. The role of proteomes in the detection, diagnosis and treatment of ALL and CLL was examined separately. Overall, the findings of this study confirm the viability of proteome analysis in profiling lymphocytic leukemia; and highlight novel leukemia biomarkers and potential therapeutic targets.
Topics: Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteome; Proteomics
PubMed: 29394974
DOI: 10.29271/jcpsp.2018.02.133 -
The Medical Clinics of North America May 1961
Topics: Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid
PubMed: 13722601
DOI: 10.1016/s0025-7125(16)33875-5 -
Journal of Clinical Oncology : Official... Jul 1987
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Leukemia, Lymphoid; Prognosis; Risk
PubMed: 3474360
DOI: 10.1200/JCO.1987.5.7.997 -
Blood Cells 1987In recent years important advances have been made in predicting the survival of patients with chronic lymphocytic leukemia (CLL). Other prognostic factors in addition to... (Review)
Review
In recent years important advances have been made in predicting the survival of patients with chronic lymphocytic leukemia (CLL). Other prognostic factors in addition to clinical staging systems have proved to be of value. Among them, bone marrow biopsy has emerged as a particularly useful prognostic tool. Patients with nondiffuse bone marrow involvement survive longer than those with diffuse involvement. This parameter is useful for subclassifying clinical stages in low- (nondiffuse patterns) and high- (diffuse patterns) risk groups. The use of a combined clinicopathological staging system for CLL seems advisable.
Topics: Biopsy; Bone Marrow; Humans; Leukemia, Lymphoid; Neoplasm Staging; Prognosis
PubMed: 3304470
DOI: No ID Found -
The role of the lymphocyte in producing the clinical manifestations of chronic lymphocytic leukemia.The Medical Clinics of North America Mar 1973
Review
Topics: Anemia, Hemolytic, Autoimmune; Binding Sites, Antibody; Cells, Cultured; Epitopes; Humans; Lectins; Leukemia, Lymphoid; Lymphocyte Activation; Lymphocytes; Pleural Effusion; Purpura, Thrombocytopenic; RNA, Ribosomal; Ribosomes; Splenomegaly
PubMed: 4120701
DOI: 10.1016/s0025-7125(16)32292-1 -
The Veterinary Clinics of North... May 1981
Review
Topics: Animals; Blood Viscosity; Cat Diseases; Cats; Diagnosis, Differential; Dog Diseases; Dogs; Female; Leukemia, Lymphoid; Male; Multiple Myeloma
PubMed: 7032049
DOI: 10.1016/s0195-5616(81)50033-7